OUR MISSION

Hope Lives Here

The mission of Mary Crowley Cancer Research is to bring hope to cancer patients through innovative clinical trials while advancing treatment for patients in the future.

OUR VISION

Reaching Toward Future

Mary Crowley Cancer Research works to find potentially curative treatments for cancer patients through clinical trial testing.  Our patient-specific approach uniquely aligns an individual’s cancer with the newest discoveries in personalized genomic and immune therapies. Mary Crowley advances science and HOPE for cancer patients worldwide.

strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background
strand background

OUR HISTORY

History of Mary Crowley Cancer Research

Mary C. Crowley established Mary Crowley Cancer Research in 1997. The center began in downtown Dallas and expanded to ten locations throughout the U.S. Today, the research center operates on the Medical City campus in north Dallas. It consistently follows FDA guidelines and has tested investigational therapies from more than 300 pharmaceutical companies, serving patients from the U.S. and multiple countries.

1957

Mary Crowley establishes Home Interiors & Gifts; she is also diagnosed with cervical cancer and treated by John T. Mallams, M.D., with experimental radiation therapy

1959-84

Her cancer in remission, Mary builds Home Interiors & Gifts into a billion dollar company

1960’s-80’s

Surgery chemotherapy and radiation become standard of care for cancer treatment

1984

Mary’s cancer recurs; she is shocked to learn that little progress has been made in treatment options for cancer patients

1986

Mary forms the Mary Crowley Medical Research Program Honoring John T. Mallams M.D. before she passes away

1988

The Board conceives the vision of opening a clinical trial program and facility at Baylor Medical Center

1994

The Board adopts clinical programs focused on molecular immune and gene therapy.

1997

The Board votes to form an independent, non-profit organization that becomes Mary Crowley Cancer Research

2007

Benevolence Fund assisting underserved patients established by Rees-Jones Foundation grant

2008

Clinical Research site relocates to Medical City campus to improve patient access

2012

Pediatric Research Program established for Ewing’s sarcoma patients

2012

Target the Target Program instituted; patient molecular information aligns patients to targeted clinical trials

2017

Mary Crowley Cancer Research celebrates 20 years of bringing HOPE to cancer patients through the evolution of personalized medicine

OUR TEAM

Dedicated to Bringing Hope

profile

Minal Barve, MD

Executive Medical Director

profile

James Strauss, MD

Clinical Scientific Director

profile

Jairo Olivares, MD

Physician Investigator

profile

Douglas W. Orr, MD

Physician Investigator

profile

Reva Schneider, MD

Physician Investigator

profile

Gilberto Jimenez-Justiniano, MD

Physician Investigator

profile

Robert Mennel, MD

Physician Investigator

profile

Leah Plato, PA-C, MPH, CCRP

Associate Director of Clinical & Scientific Operations

profile

Ntombizodwa “Zodwa“ Sayi, MSN, RN, AGPCNP-BC

Nurse Practitioner

profile

Jenifer Mallow

Nurse Practitioner

profile

Jennifer Fox, MBA

Chief Executive Officer & Board Member

profile

Minal Barve, MD

Executive Medical Director

profile

Deborah Montonen, CFRE

Vice President and Chief Development Officer

profile

Stacy Meador

Vice President of Finance

profile

Natalie Settele

VP of Clinical Research Operations

profile

Roy W. Lamkin

Chair Of The Board

profile

Scott Bradley Burris, MD

Vice Chair Of the Board

profile

Adil Adi

Board Member

profile

Vincent Bush

Board Member

profile

Ron Carter

Board Member

profile

Edwin Flores

Board Member

profile

Jennifer Fox, MBA

Chief Executive Officer & Board Member

profile

Tom Hulsey

Board Member

profile

Thomas B. Hoyt

Board Member

profile

Michael Kearins

Board Member

profile

Edward W. Marx

Board Member

profile

Rodney G. Olsen

Board Member

profile

Mary Elizabeth Warner

Board Member

PHARMACEUTICAL COLLABORATORS

An Accelerated Approach to Cancer Research

Mary Crowley Cancer Research has conducted 740+ clinical trials for 7400+ patients in collaboration with 300+ different pharmaceutical partners. MCCR is designed, equipped, and staffed for conducting early phase solid tumor and hematology trials, including performing 129+ first-in-human trials. Outpatient and inpatient hospital support, and a dedicated referral and consult team. MCCR has completed phase I and phase II, industry funded studies including first-in-human, drug-drug interaction, food effect, bioequivalence, and intensive EKG monitoring studies. This site has experience using gene therapies, cytokines, cytotoxic agents, cellular therapies, small molecules, viral therapies, monoclonal antibodies, antibody drug conjugates, immune therapy, and vaccines.

Study Start-Up
  • 8 – 10 weeks from receipt of final protocol – may be shorter under our Just-in-Time (JIT) program
  • Parallel completion of all startup activities
  • Prompt review/approval – local Institutional Review Board meets weekly

Our Site Location

Welcome to Our Clinic

The Administrative Offices

  • 16,000 square foot administrative office space
  • Dedicated research employees (Finance, Legal, Project Management, Regulatory, IRB, Marketing/Business Development, Leadership)
  • Monitoring suites with high-speed internet access

Our Clinic at Medical City Dallas

The Clinic

  • State-of-the-Art, 14,000 square foot clinic located on the campus of Medical City Hospital, Dallas.
  • Dedicated research clinical staff (CRNs, CRC, PharmD, and supporting personnel)
  • 13 infusion chairs
    Integrated research-only pharmacy
    BSL II compliant isolation rooms
    Specialized laboratory processing (including PBMCs)

Location

  • 7777 Forest Lane,
    Building C-707
    Dallas, TX 75230
  • 972.566.3000

Patient Populations

  • Referral base of over 420 oncologists
  • Robust Molecular Registry – reportable for rapid enrollment
  • Outreach team focused on educating community oncologists of trials and their technology

Data Timelines

  • 70/70 Successful MQA Audits
  • 6/6 Successful FDA Audits
  • Data team located within clinic to expedite data entry timelines

Providing Hope with Innovative Cancer Treatments

With a mission to bring hope, patient-centric focus brings the newest clinical trial options to patients at a rapid pace.

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000